期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 10, 期 3, 页码 143-153出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2013.10
关键词
-
类别
The phosphatidylinositol 3-kinase (PI3K) pathway has an important role in cell metabolism, growth, migration, survival and angiogenesis. Drug development aimed at targetable genetic aberrations in the PI3K/AKT/mTOR pathway has been fomented by observations that alterations in this pathway induce tumour formation and that inappropriate PI3K signalling is a frequent occurrence in human cancer. Many of the agents developed have been evaluated in early stage clinical trials. This Review focuses on early clinical and translational data related to inhibitors of the PI3K/AKT/mTOR pathway, as these data will likely guide the further clinical development of such agents. We review data from those trials, delineating the safety profile of the agents-whether observed sequelae could be mechanism-based or off-target effects-and drug efficacy. We describe predictive biomarkers explored in clinical trials and preclinical mechanisms of resistance. We also discuss key unresolved translational questions related to the clinical development of inhibitors of the PI3K/AKT/mTOR pathway and propose designs for biomarker-driven trials to address those issues. Rodon, J. etal. Nat. Rev. Clin. Oncol. 10,143-153; published online 12 February 2013; doi:10.1038/nrclinonc.2013.10
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据